Limits...
Efficacy of Setarud (IMOD™), a novel electromagnetically-treated multi-herbal compound, in mouse immunogenic type-1 diabetes.

Mohseni-Salehi-Monfared SS, Habibollahzadeh E, Sadeghi H, Baeeri M, Abdollahi M - Arch Med Sci (2010)

Bottom Line: In the pancreas tissue, the level of lipid peroxidation as thiobarbituric acid reactive substances (TBARS), total antioxidant power as ferric reducing ability of pancreas (FRAP), myeloperoxidase (MPO), and the concentrations of interleukin-1 (IL-1β) and tumour necrosis factor-α (TNF-α) were evaluated.No significant difference was found between IMOD™ and diabetic control groups in blood glucose pattern.Co-administration of IMOD™ significantly improved all the mentioned parameters disrupted by STZ administration except for blood glucose and histological changes.

View Article: PubMed Central - PubMed

Affiliation: Faculty of Pharmacy, and Pharmaceutical Sciences Research Centre, Tehran University of Medical Sciences, Tehran, Iran.

ABSTRACT

Introduction: The aim of this study was to evaluate the effects and mechanisms of Setarud (IMOD™) as a multi-herbal medicinal formula on a mouse model of type 1 diabetes. METERIAL AND METHODS: Autoimmune diabetes was induced by multiple low-dose intraperitoneal injection of 40 mg/kg of streptozotocin (STZ) for five consecutive days. IMOD™ was administered at an effective dose of 20 mg/kg/day for 21 days. After 21 days of treatment, the pancreases of the animals were separated and homogenized. In the pancreas tissue, the level of lipid peroxidation as thiobarbituric acid reactive substances (TBARS), total antioxidant power as ferric reducing ability of pancreas (FRAP), myeloperoxidase (MPO), and the concentrations of interleukin-1 (IL-1β) and tumour necrosis factor-α (TNF-α) were evaluated. Glucose changes were tested in the blood. Microscopic changes in the pancreas were followed by histological examinations.

Results: No significant difference was found between IMOD™ and diabetic control groups in blood glucose pattern. STZ-exposed mice showed a significant increase in pancreatic TBARS, MPO, IL-1β, and TNF-α levels, along with a significant decrease in FRAP value. Co-administration of IMOD™ significantly improved all the mentioned parameters disrupted by STZ administration except for blood glucose and histological changes.

Conclusion: IMOD™ could ameliorate oxidative and immunological distresses of type-1 immunogenic diabetes but could not normalize blood glucose. Further studies are recommended to clarify the effects of IMOD™ on immunological factors to address whether this new agent could be applied in diabetes prevention or therapy.

No MeSH data available.


Related in: MedlinePlus

Pancreatic level of oxidative stress markers in experimental groups on day 21. IMOD™ (20 mg/kg/d, IP) decreased MPO activity (A) and lipid peroxidation, assessed by TBARS concentration (B), in pancreas samples of treated mice. Total antioxidant power (FRAP) of pancreatic tissue increased in IMODTM treated groups (C)*p < 0.01 comparing with ND-C; **p < 0.01 comparing with D-C
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3298332&req=5

Figure 2: Pancreatic level of oxidative stress markers in experimental groups on day 21. IMOD™ (20 mg/kg/d, IP) decreased MPO activity (A) and lipid peroxidation, assessed by TBARS concentration (B), in pancreas samples of treated mice. Total antioxidant power (FRAP) of pancreatic tissue increased in IMODTM treated groups (C)*p < 0.01 comparing with ND-C; **p < 0.01 comparing with D-C

Mentions: Following administration of IMOD™, oxidative stress indicators including MPO activity, FRAP, and TBARS were measured in pancreatic specimens of animals at the end of the study (day 21). Figure 2A shows MPO activity between groups. There was a significant difference between diabetic and other groups in MPO activity (p < 0.05). There was a significant decrease of MPO activity in IMOD™-treated diabetic mice compared to the diabetic control group (p < 0.05).


Efficacy of Setarud (IMOD™), a novel electromagnetically-treated multi-herbal compound, in mouse immunogenic type-1 diabetes.

Mohseni-Salehi-Monfared SS, Habibollahzadeh E, Sadeghi H, Baeeri M, Abdollahi M - Arch Med Sci (2010)

Pancreatic level of oxidative stress markers in experimental groups on day 21. IMOD™ (20 mg/kg/d, IP) decreased MPO activity (A) and lipid peroxidation, assessed by TBARS concentration (B), in pancreas samples of treated mice. Total antioxidant power (FRAP) of pancreatic tissue increased in IMODTM treated groups (C)*p < 0.01 comparing with ND-C; **p < 0.01 comparing with D-C
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3298332&req=5

Figure 2: Pancreatic level of oxidative stress markers in experimental groups on day 21. IMOD™ (20 mg/kg/d, IP) decreased MPO activity (A) and lipid peroxidation, assessed by TBARS concentration (B), in pancreas samples of treated mice. Total antioxidant power (FRAP) of pancreatic tissue increased in IMODTM treated groups (C)*p < 0.01 comparing with ND-C; **p < 0.01 comparing with D-C
Mentions: Following administration of IMOD™, oxidative stress indicators including MPO activity, FRAP, and TBARS were measured in pancreatic specimens of animals at the end of the study (day 21). Figure 2A shows MPO activity between groups. There was a significant difference between diabetic and other groups in MPO activity (p < 0.05). There was a significant decrease of MPO activity in IMOD™-treated diabetic mice compared to the diabetic control group (p < 0.05).

Bottom Line: In the pancreas tissue, the level of lipid peroxidation as thiobarbituric acid reactive substances (TBARS), total antioxidant power as ferric reducing ability of pancreas (FRAP), myeloperoxidase (MPO), and the concentrations of interleukin-1 (IL-1β) and tumour necrosis factor-α (TNF-α) were evaluated.No significant difference was found between IMOD™ and diabetic control groups in blood glucose pattern.Co-administration of IMOD™ significantly improved all the mentioned parameters disrupted by STZ administration except for blood glucose and histological changes.

View Article: PubMed Central - PubMed

Affiliation: Faculty of Pharmacy, and Pharmaceutical Sciences Research Centre, Tehran University of Medical Sciences, Tehran, Iran.

ABSTRACT

Introduction: The aim of this study was to evaluate the effects and mechanisms of Setarud (IMOD™) as a multi-herbal medicinal formula on a mouse model of type 1 diabetes. METERIAL AND METHODS: Autoimmune diabetes was induced by multiple low-dose intraperitoneal injection of 40 mg/kg of streptozotocin (STZ) for five consecutive days. IMOD™ was administered at an effective dose of 20 mg/kg/day for 21 days. After 21 days of treatment, the pancreases of the animals were separated and homogenized. In the pancreas tissue, the level of lipid peroxidation as thiobarbituric acid reactive substances (TBARS), total antioxidant power as ferric reducing ability of pancreas (FRAP), myeloperoxidase (MPO), and the concentrations of interleukin-1 (IL-1β) and tumour necrosis factor-α (TNF-α) were evaluated. Glucose changes were tested in the blood. Microscopic changes in the pancreas were followed by histological examinations.

Results: No significant difference was found between IMOD™ and diabetic control groups in blood glucose pattern. STZ-exposed mice showed a significant increase in pancreatic TBARS, MPO, IL-1β, and TNF-α levels, along with a significant decrease in FRAP value. Co-administration of IMOD™ significantly improved all the mentioned parameters disrupted by STZ administration except for blood glucose and histological changes.

Conclusion: IMOD™ could ameliorate oxidative and immunological distresses of type-1 immunogenic diabetes but could not normalize blood glucose. Further studies are recommended to clarify the effects of IMOD™ on immunological factors to address whether this new agent could be applied in diabetes prevention or therapy.

No MeSH data available.


Related in: MedlinePlus